The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | L | Antineoplastic and immunomodulating agents | |
| 2 | L01 | Antineoplastic agents | |
| 3 | L01B | Antimetabolites | |
| 4 | L01BB | Purine analogues | |
| 5 | L01BB07 | Nelarabine |
| Active Ingredient | Description | |
|---|---|---|
| Nelarabine |
Nelarabine is a pro-drug of the deoxyguanosine analogue ara-G. Accumulation of ara-GTP in leukaemic blasts allows for preferential incorporation of ara-GTP into deoxyribonucleic acid (DNA) leading to inhibition of DNA synthesis. This results in cell death. Other mechanisms may contribute to the cytotoxic effects of nelarabine. In vitro, T-cells are more sensitive than B-cells to the cytotoxic effects of nelarabine. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| ATRIANCE Solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
